RSLS - ReShape Lifesciences Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.5050
-0.0150 (-2.88%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.5200
Open0.5200
Bid0.51 x 1200
Ask0.53 x 2200
Day's Range0.4950 - 0.5390
52 Week Range0.4900 - 3,759.0000
Volume415,709
Avg. Volume1,150,865
Market Cap3.858M
Beta (3Y Monthly)2.05
PE Ratio (TTM)N/A
EPS (TTM)-876.51
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.00
Trade prices are not sourced from all markets
  • ACCESSWIRE9 days ago

    ReShape Lifesciences Expands International Business in the Middle East

    In January 2019, Dr. Haya Ahmed Khalfan Isa Khalfan, Consultant General Surgeon at BDF Military Hospital in Bahrain will be trained at a facility in the United States on using the ReShape Balloon. Dr. Khalfan will be the first surgeon in Bahrain to be trained on the ReShape Balloon.

  • ACCESSWIRE12 days ago

    ReShape Lifesciences Announces Live Surgery Course for ReShape Vest

    SAN CLEMENTE, CA / ACCESSWIRE / December 3, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that the Company will be holding a live-surgery surgical training for bariatric surgeons and key opinion leaders who will serve as investigators in the Company's ENDURE II trial in the European Union. The training will occur on February 4-5, 2019, in Prague, Czech Republic and is designed to provide practical experience to support initiation of the Company's ENDURE II trial in early Q1 2019. The ReShape Lifesciences ENDURE II trial is an investigative, prospective, non-randomized, multi-center study to assess the safety and effectiveness of the Reshape Vest for treatment of obese patients.

  • ACCESSWIRE16 days ago

    ReShape Lifesciences Provides Financing and Corporate Update

    As a result of the aggregate $25 million in gross proceeds raised in these recent financings and the Company's continued efforts to manage its expenses, the Company believes that it should have sufficient capital to fund its current operations into 2020. "We are really pleased with the progress we have made in getting our capital structure back to health," said Dan Gladney, Chief Executive Officer and Chairman of the Board of ReShape Lifesciences.

  • ACCESSWIRE18 days ago

    Today's Research Reports on Trending Tickers: Novelion Therapeutics and ReShape Lifesciences

    ReShape announced several encouraging developments including data regarding the treatment of type 2 diabetes mellitus but saw its shares sold off. Novelion Therapeutics Inc. shares were up 7.61% at the close yesterday with roughly 2% more seen in after-hours trading in gains. There was no significant news from the company yesterday but it was last week that the biopharmaceutical company said that General Counsel, Benjamin Harshbarger, has been appointed as interim CEO, reporting to Novelion’s Executive Chair, Mark Corrigan, M.D., effective immediately.

  • ACCESSWIRE19 days ago

    4 Healthcare Stocks Seeing New Highs On Monday

    CORAL GABLES, FL / ACCESSWIRE / November 26, 2018 / Healthcare stocks remain popular during the latest bout of selling pressure within the broader markets. The Frost & Sullivan Healthcare and Life Sciences experts are predicting big disruptions, transformationsand innovations in the coming years as the healthcare industry continues to overhaul outmoded business models. "Our interactive workshop is designed to help managers and CEOs understand key issues affecting the healthcare industry globally," noted Sandeep Sinha, Vice President & Head, Healthcare and Life Sciences, Frost & Sullivan.

  • ACCESSWIRE19 days ago

    ReShape Lifesciences Announces $10 Million Registered Direct Offering

    SAN CLEMENTE, CA / ACCESSWIRE / November 26, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it has entered into definitive agreements with two healthcare focused institutional investors for the purchase of 8,000,000 shares of its common stock and warrants to purchase 8,000,000 shares of its common stock, at a purchase price of $1.25 per share and associated warrants, for gross proceeds of approximately $10 million, in a registered direct offering. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The warrants have an exercise price of $1.50 per share of common stock, will be exercisable immediately and will expire five years from the issuance date.

  • ACCESSWIRE19 days ago

    ReShape Lifesciences Presents New Data on Proprietary Technology for Type 2 Diabetes

    SAN CLEMENTE, CA / ACCESSWIRE / November 26, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced new data that was presented during a poster presentation at the recent ObesityWeek 2018 conference in Nashville, Tennessee. The poster presentation, titled "Dual Vagus Neuromodulation Improves Glycemic Control in Obese Rat and Pig Models of Type 2 Diabetes," discussed a proprietary technique developed by ReShape Lifesciences that utilizes the Company's vBlocTM technology to stimulate nerves feeding into the pancreas while simultaneously blocking nerves feeding into the liver.

  • ACCESSWIRElast month

    ReShape Lifesciences Announces Third Quarter 2018 Financial Results

    SAN CLEMENTE, CA / ACCESSWIRE / November 14, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today reported financial ...

  • ACCESSWIRElast month

    4 Healthcare Stocks Investors Should Get Familiar With

    CORAL GABLES, FL / ACCESSWIRE / November 14, 2018 / The healthcare sector is the sector of the economy made up of companies that specialize in products and services related to health and medical care. As the industry continues to emerge as a leading place for investors to hedge against broader market volatility, companies like Premier Health Group, Inc. (PHGRF) (PHGI), ReShape Lifesciences Inc. (RSLS), Teladoc (TDOC), and Imprimis Pharmaceuticals, Inc. (IMMY). Premier Health Group, Inc. (PHGRF) (PHGI) is focused on developing innovative approaches that combine human skill based expertise with emerging technologies for the healthcare industry.

  • ACCESSWIRElast month

    Today’s Research Reports on Stocks to Watch: ReShape Lifesciences and ABIOMED

    NEW YORK, NY / ACCESSWIRE / November 13, 2018 / It was a day of red for ReShape Lifesciences and ABIOMED on Monday. Both stocks had double digit losses despite encouraging developments reported. RDI Initiates ...

  • ACCESSWIRElast month

    3 Health Care Stocks Making Moves On Monday; Premier Health Group, Inc. (OTC: PHGRF) (CSE: PHGI), Lannett Company, ReShape Lifesciences

    CORAL GABLES, FL / ACCESSWIRE / November 12, 2018 / New trends in Healthcare have helped push biotechnology stocks and healthcare stocks higher this year. Connected health is a new model for healthcare delivery, which provides healthcare services remotely. According to reports* the global connected healthcare market is expected to reach $105,337.5 Million by 2022 at a CAGR of 30.27% during the forecast period.

  • ACCESSWIRElast month

    ReShape Lifesciences Completes Investigator Meeting for ReShape Vest Clinical Trial in the European Union

    SAN CLEMENTE, CA ACCESSWIRE / November 12, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that on November 7, 2018 the company conducted an investigator meeting in conjunction with the trial in the European Union to support CE Marking of the ReShape Vest.TM The investigator meeting took place in Frankfurt, Germany and was intended to further establish relationships with the study team and to prepare investigators for the upcoming clinical trial for the ReShape Vest. Ten bariatric surgeons from The Netherlands, the Czech Republic, Germany and Belgium met with a team from ReShape Lifesciences and the group discussed the ReShape Vest technology and its proper surgical technique for use in addition to reviewing the trial protocol in anticipation of initiating study enrollment.

  • ACCESSWIRElast month

    3 Health Care Stocks Seeing Heightened Activity After Midterms

    Sesen Bio, Inc. (SESN) saw a stronger premarket session on Thursday morning. "2018 has been a year of focused execution for Sesen Bio, led by the advancement of the Phase 3 program for Vicinium for patients with NMIBC," said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio.

  • ACCESSWIRElast month

    ReShape Lifesciences Announces National VA Contract for ReShape Balloon

    SAN CLEMENTE, CA / ACCESSWIRE / November 8, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that ...

  • ACCESSWIRElast month

    ReShape Lifesciences Announces 1-for-140 Reverse Stock Split

    SAN CLEMENTE, CA / ACCESSWIRE / November 7, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that its Board of Directors has declared a 1-for-140 reverse stock split of the company's common stock, which will be effective for trading purposes upon the commencement of trading on November 8, 2018. At that time, each 140 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock. As a result of the reverse stock split, proportional adjustments will be made to the number of shares of common stock issuable upon exercise or conversion, and the per share exercise or conversion price, of the company's outstanding warrants, stock options and convertible preferred stock, in each case in accordance with their terms.

  • ACCESSWIRElast month

    ReShape Lifesciences to Host Third Quarter 2018 Conference Call on November 14, 2018

    SAN CLEMENTE, CA / ACCESSWIRE / October 31, 2018 / ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that ...

  • ACCESSWIRE2 months ago

    ReShape Lifesciences Announces Retirement of Series D Preferred Stock

    SAN CLEMENTE, CA / ACCESSWIRE / October 29, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that as of Friday, October 19, 2018, all shares of the Company's Series D Preferred Stock have been converted into ReShape Lifesciences common shares. The Company used the net proceeds from this offering to continue its commercialization efforts, clinical and product development activities, and for other working capital and general corporate purposes. "We are very pleased with the increased financial flexibility the retirement of these shares represent as we continue to set the Company up to finance our working capital requirements, including our upcoming ReShape VestTM trials," stated Dan Gladney, President and Chief Executive Officer.

  • ACCESSWIRE2 months ago

    ReShape Lifesciences Announces Attendance and Presentation at ObesityWeek 2018

    SAN CLEMENTE, CA / ACCESSWIRE / October 25, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that ...

  • ACCESSWIRE2 months ago

    ReShape Lifesciences Announces Investigator Meeting for ReShape Vest Clinical Trial in European Union

    SAN CLEMENTE, CA / ACCESSWIRE / October 8, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that ...

  • ACCESSWIRE2 months ago

    ReShape Lifesciences Presents New Data on Extension of Weight Loss with ReShape Patient Portal

    SAN CLEMENTE, CA / ACCESSWIRE / October 4, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that ...

  • ACCESSWIRE3 months ago

    ReShape Lifesciences Announces Acceptance of Abstract to be Presented at ObesityWeek 2018

    SAN CLEMENTE, CA / ACCESSWIRE / September 24, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that the company has had an abstract accepted by the scientific committee of The Obesity Society. Professor of Medicine, University of Minnesota, during ObesityWeek 2018, an annual meeting co-sponsored by the American Society for Metabolic and Bariatric Surgery (ASMBS) and The Obesity Society (TOS), which is taking place in Nashville, TN on November 15, 2018.

  • ACCESSWIRE3 months ago

    ReShape Lifesciences Announces Poster at IFSO Annual Conference

    SAN CLEMENTE, CA / ACCESSWIRE / September 21, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today ...

  • ACCESSWIRE3 months ago

    ReShape Lifesciences Announces Pricing of Public Offering

    SAN CLEMENTE, CA / ACCESSWIRE / September 18, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced the pricing of its previously announced public offering of 11,688,890 shares of its common stock and warrants to purchase up to 5,844,445 shares of its common stock, at a public offering price of $0.045 per share and associated warrant. The gross proceeds from the offering, before deducting placement agent fees and estimated offering expenses payable by ReShape Lifesciences, are expected to be approximately $0.52 million. All of the securities in the offering are to be sold by ReShape Lifesciences.

  • ACCESSWIRE3 months ago

    ReShape Lifesciences Announces Proposed Public Offering

    SAN CLEMENTE, CA / ACCESSWIRE / September 14, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it has commenced a public offering of shares of its common stock and warrants to purchase shares of its common stock. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the securities in the proposed offering are to be sold by ReShape Lifesciences.

  • ACCESSWIRE3 months ago

    ReShape Lifesciences Announces New Patent Grant Expanding its Gastric Vest Patent Portfolio

    SAN CLEMENTE, CA / ACCESSWIRE / September 6, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that The State Intellectual Property Office of The People's Republic of China has granted a device patent to the Company that expands the patent portfolio for the ReShape VestTM. ''We are very excited about this patent that helps protect our proprietary, minimally invasive, novel technology to address the significant obesity market in China,'' said Dan Gladney, Chief Executive Officer and Chairman of the Board of ReShape Lifesciences. Research by Imperial College London found that China's obesity rate has skyrocketed in the last 30 years to one of the highest obesity rates in the world.